Arsenic trioxide control release elution stent

A technology of arsenic trioxide and eluting stents, which is applied in the fields of drugs and medical devices to induce apoptosis, inhibit intimal hyperplasia, and prevent restenosis
CN1657023AInactive Publication Date: 2005-08-24SHANGHAI FIRST PEOPLES HOSPITAL
0 Cites 21 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANGHAI FIRST PEOPLES HOSPITAL
Publication Date
2005-08-24
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

An elution stent with controlled release of As2O3 for preventing and treating coronary heart disease features that the As2O3 is used as the stent medicine and the dual coated layers including the coated butyl polymethylatel nano-SiO2 layer and the coated PLGA layer are used to control the release of As2O3 for inducing the wither of smooth muscle cells at the second stage of damaged blood vessel.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of drugs and medical devices, and relates to a drug-eluting stent for preventing restenosis after implantation of a coronary artery stent, in particular to an arsenic trioxide controlled-release eluting stent. Background technique

[0002] At present, one of the main problems in the field of coronary interventional cardiology is restenosis after stent implantation. A large number of research results show that systemic medication cannot obtain satisfactory results. Drug-eluting stents, which use stents as delivery carriers and allow drugs to act locally in damaged coronary arteries, have the advantages of high local drug concentration and low systemic side effects, and are expected to become an effective way to solve restenosis after stent implantation. The proliferation and migration of vascular smooth muscle cells (SMC) is the main cause of vascular intimal hyperplasia and restenosis. At present, most drugs are selec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More